Improvement in naltrexone treatment compliance with contingency management

被引：120

作者：

Preston, KL ^{[1
]}

Silverman, K ^{[1
]}

Umbricht, A ^{[1
]}

DeJesus, A ^{[1
]}

Montoya, ID ^{[1
]}

Schuster, CR ^{[1
]}

机构：

[1] NIH, Addict Res Ctr, NIDA, Intramural Res Program, Baltimore, MD 21224 USA

来源：

DRUG AND ALCOHOL DEPENDENCE | 1999年 / 54卷 / 02期

关键词：

naltrexone; opioid-dependence; treatment; contingency management; treatment compliance;

D O I：

10.1016/S0376-8716(98)00152-5

中图分类号：

R194 [卫生标准、卫生检查、医药管理];

学科分类号：

摘要：

The efficacy of a voucher-based incentive program for improving adherence to outpatient, thrice weekly naltrexone maintenance was tested in a three group, randomized, la-week clinical trial. Voucher incentives were given as follows: contingent group (n = 19) for each consecutive naltrexone dose ingested; non-contingent group (n = 19) on unpredictable schedule independently of taking naltrexone; no-voucher group (pr = 20) none. Vouchers were exchangeable for goods and services. The contingent group had significantly longer treatment retention and ingested significantly more doses of naltrexone (consecutive and total) than either control group. Voucher incentives can significantly increase adherence to naltrexone maintenance in recently detoxified opioid dependent individuals. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：127 / 135

页数：9

共 33 条

[1]

[Anonymous], 1995, FEDERAL REGULATION M

[2] THE MEDICAL COMPLICATIONS OF DRUG-ADDICTION AND THE MEDICAL ASSESSMENT OF THE INTRAVENOUS-DRUG-USER - 25 YEARS LATER [J].

CHERUBIN, CE ;

SAPIRA, JD .

ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) :1017-1028

[3] Naltrexone pharmacotherapy for opioid dependent federal probationers [J].

Cornish, JW ;

Metzger, D ;

Woody, GE ;

Wilson, D ;

McLellan, AT ;

Vandergrift, B ;

O'Brien, CP .

JOURNAL OF SUBSTANCE ABUSE TREATMENT, 1997, 14 (06) :529-534

[4]

CROWLEY TJ, 1985, AM J PSYCHIAT, V142, P1081

[5] Estimating the dollar value of health outcomes from drug-abuse interventions [J].

French, MT ;

Mauskopf, JA ;

Teague, JL ;

Roland, EJ .

MEDICAL CARE, 1996, 34 (09) :890-910

[6] NALTREXONE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN THE MANAGEMENT OF OPIOID DEPENDENCE [J].

GONZALEZ, JP ;

BROGDEN, RN .

DRUGS, 1988, 35 (03) :192-213

[7] SEVERITY OF HEROIN DEPENDENCE AND HIV RISK .2. SHARING INJECTING EQUIPMENT [J].

GOSSOP, M ;

GRIFFITHS, P ;

POWIS, B ;

STRANG, J .

AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 1993, 5 (02) :159-168

[8] EFFECTS OF CONTINGENT PAYMENT ON COMPLIANCE WITH A NALTREXONE REGIMEN [J].

GRABOWSKI, J ;

OBRIEN, CP ;

GREENSTEIN, R ;

TERNES, J ;

LONG, M ;

STEINBERGDONATO, S .

AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 1979, 6 (03) :355-365

[9] PREDICTORS OF FAVORABLE OUTCOME FOLLOWING NALTREXONE TREATMENT [J].

GREENSTEIN, RA ;

EVANS, BD ;

MCLELLAN, AT ;

OBRIEN, CP .

DRUG AND ALCOHOL DEPENDENCE, 1983, 12 (02) :173-180

[10]

HARRIGAN SE, 1978, J PHARMACOL EXP THER, V204, P481

← 1 2 3 4 →